



Breakthrough SARS-CoV-2 infection in fully vaccinated patients with systemic lupus erythematosus: results from the COVID-19 Vaccination in Autoimmune Disease (COVAD) study

Leonardo Palazzo¹ · Julius Lindblom¹ · Emelie Kihlgren Olsson¹ · Elena Nikiphorou^{2,3} · Chris Wincup^{4,5} · Sreoshy Saha⁶ · Syahrul Sazliyana Shaharir⁷ · Wanruchada Katchamart⁸ · Phonpen Akarawatcharangura Goo⁹ · Lisa Traboco¹⁰ · Yi-Ming Chen^{11,12} · James B. Lilleker^{13,14} · Arvind Nune¹⁵ · John D. Pauling^{16,17} · Vishwesh Agarwal¹⁸ · Dey Dzifa¹⁹ · Carlos Enrique Toro Gutiérrez²⁰ · Carlo V. Caballero-Urbe²¹ · Hector Chinoy^{13,22,23} · COVAD Study Group · Vikas Agarwal²⁴ · Latika Gupta^{13,25} · Ioannis Parodis^{1,26}

Received: 5 July 2024 / Accepted: 3 August 2024
© The Author(s) 2024

Abstract

Objective To determine the occurrence of breakthrough COVID-19 infections (BIs) in patients with systemic lupus erythematosus (SLE) compared with patients with other rheumatic autoimmune diseases (rAIDs), patients with non-rheumatic autoimmune diseases (nrAIDs), and healthy controls (HCs).

Methods The study was based on data from 7035 fully vaccinated respondents to the online COVAD questionnaire with SLE (N=852), rAIDs (N=3098), or nrAIDs (N=414), and HCs (N=2671). BI was defined as COVID-19 infection occurring in individuals vaccinated with ≥ 2 doses (or 1 dose of J&J) ≥ 14 days after vaccination and not after 6 months since the last vaccine dose. Data were analysed using linear and logistic regression models.

Results A total of 91/852 (10.7%) SLE patients reported at least one BI. The frequency of BIs in SLE patients was comparable to that among HCs (277/2671; $p=0.847$) and patients with nrAID (39/414; $p=0.552$) but higher than that among patients with other rAIDs (235/3098; $p=0.005$). No demographic factors or treatments were associated with BIs in SLE patients ($p \geq 0.05$ for all). Joint pain was more frequent in SLE patients than in HCs (odds ratio [OR]: 3.38; 95% confidence interval [CI]: 1.89–6.04; $p < 0.001$) or nrAID patients (OR: 2.44; 95% CI: 1.04–5.75; $p = 0.041$). Patient with SLE did not report a higher frequency of hospitalisation or need for advanced treatment for COVID-19 infection compared with disease controls and HCs, respectively.

Conclusion COVID-19 vaccination conferred similar protection against COVID-19 infection in terms of frequency and severity in patients with SLE to that reported by healthy individuals.

Keywords COVID-19 · Vaccination · Breakthrough infection · Systemic lupus erythematosus · Rheumatology · Autoimmune disease · Survey

Introduction

The health consequences of coronavirus disease 2019 (COVID-19) infections have abated since the start of vaccination against the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), which translates into less severe infections, decreased mortality rates, and lower hospitalisation rates [1–4]. A 10% increase in vaccination coverage has been reported to result in a 7% incidence reduction and 8% reduction in mortality from breakthrough infections (BIs) in the vaccinated healthy population [5]. The symptoms

Vikas Agarwal and Ioannis Parodis have contributed equally as senior authors.

The complete list of members of the COVAD Study Group as well as their affiliations are provided in the Supplementary Material.

Extended author information available on the last page of the article

of COVID-19 infections have also been reported to be less severe in vaccinated compared with unvaccinated individuals [6].

Previous studies have suggested that in comparison with the general population, patients with rheumatic autoimmune diseases (rAIDs) such as systemic lupus erythematosus (SLE) are at higher risk of severe COVID-19 infection, yielding a hospitalisation frequency of 58% and mortality of 7% [7]. In patients with SLE, several factors may increase the vulnerability to severe COVID-19, including associated comorbidities and immunosuppressive treatments [8]. While glucocorticoids (GCs) are associated with a higher risk of hospitalisation due to COVID-19 infections [9, 10], the influence of other medications given for SLE, including conventional immunosuppressive drugs and biologics, still is controversial, and previous studies have reported conflicting results [9–12]. In addition, impaired immune responses in SLE patients, especially in those receiving immunosuppressive treatments, threatens vaccine effectiveness [13, 14].

As per current knowledge, recommendations suggest that the benefits from vaccination in people with rAIDs, including SLE, far outweigh the concerns related to ineffectiveness and vaccine-induced adverse events (AEs) [15, 16]. However, surveys on rAID patients' attitudes to vaccination have reported vaccine hesitancy rates as high as 35%, with main concerns being uncertainty regarding vaccine safety and fear of vaccine-induced disease flares [17].

We recently showed that despite discrepancies across COVID-19 vaccines regarding a few minor AEs, those were overall well-tolerated by SLE patients irrespective of disease activity and background therapies [18]. However, there is still a dearth of data regarding COVID-19 BIs in patients with SLE, which framed the scope of the present investigation. Among questions that have yet to be addressed is the impact of disease activity or use of immunosuppressive or immunomodulatory therapies on the protection conferred from COVID-19 vaccines in patients with SLE. The aim of this study was to investigate the prevalence, characteristics, and predictors of COVID-19 BIs in patients with SLE compared with patients with rAIDs other than SLE, patients with non-rheumatic autoimmune diseases (nrAIDs), and healthy controls (HCs).

Methods

Study design and population

An international online, cross-sectional, multicentre survey-based study was conducted between January and May 2022 within the frame of the global COVID-19 Vaccination in Autoimmune Diseases (COVAD) collaboration. People over 18 years of age diagnosed with an autoimmune disease

or considering themselves healthy answered questions regarding demographics, current medications, COVID-19 infections, and vaccination status. Some of the questions pertained to how many vaccine doses the participant had received and whether hospitalisation was required due to COVID-19 infection. The survey also included questions about symptoms during a COVID-19 infection, such as fever, cough, shortness of breath, loss of smell, loss of taste, running nose, and throat pain. In addition, participants were asked to report symptom duration for each symptom and whether advanced treatment was required for their COVID-19 infection [19, 20]. The survey did not impose any restriction to the respondents regarding the degree of disease activity or past or present organ involvement. The questionnaire was developed by international rheumatology experts based on literature review of relevant articles, and it was next pilot tested, validated, and translated into 18 languages. Details about the survey protocol and data collection are published elsewhere [19–21].

Ethics

An initial segment in the online survey served to obtain informed consent from the study participants. The results are reported in compliance with the Checklist for Reporting Results of the Internet E-surveys (CHERRIES) [22]. The ethics committee of Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS) granted approval for the study (IEC code: 2021–143-IP-EXP-39).

Clinical definitions

rAIDs listed in the questionnaire included SLE, ankylosing spondylitis, myositis and anti-synthetase syndrome, rheumatoid arthritis (RA), and systemic sclerosis (SSc), whereas nrAIDs included inflammatory bowel disease and type 1 diabetes, among others, as detailed elsewhere [20]. Survey respondents also had the option to specify their autoimmune disease in free text if not listed in the survey.

To define a BI, we adhered to the CDC's definition, considering them to occur in vaccinated respondents i.e., those who have received either ≥ 2 doses or 1 dose of Johnson & Johnson (J&J; JNJ-78436735) ≥ 14 days after vaccination and not after 6 months since the last vaccine dose. Advanced treatment was considered as treatment with monoclonal antibodies.

Statistical analysis

Descriptive data are presented as numbers (percentage) or means (standard deviation, [S.D.]), and medians (interquartile range, [IQR]) are indicated in case of non-normal distribution. The Pearson's chi-squared (χ^2) test was used to

compare categorical variables. The duration of BIs in SLE patients and comparator groups was analysed by unadjusted and adjusted (for age, sex, and ethnicity) linear regression. Results from linear regression are presented as the coefficient (β), confidence interval (CI) and p value. Factors associated with BI among patients with SLE were investigated through univariable logistic regression. Differences in BI presentation between SLE patients and comparator groups were evaluated by multivariable logistic regression, adjusting for age, sex, and ethnicity. Results from logistic regression are presented as the odds ratio (OR), CI, and p value. For all analyses, p values < 0.05 were considered statistically significant. Analyses were performed and illustrations were created using the R Statistical Software version 4.3.3 (R Foundation for Statistical Computing, Vienna, Austria).

Results

Out of 16,328 total respondents, we retrieved data from 10,783 survey respondents with complete responses. Of those, 7035 were fully vaccinated, including 852 (12.1%) patients with SLE, 3098 (44.0%) patients with rAID, 414 (5.9%) patients with nrAID, and 2671 HCs (38.0%), forming our study population (Supplementary Fig. S1). Demographics and clinical features of SLE patients and comparator groups, including self-reported disease activity status, are presented in Table 1.

Of the fully vaccinated SLE patients, 91/852 (10.7%) reported a BI. The frequency of BIs in fully vaccinated SLE patients was similar to that reported by HCs (277/2671; 10.4%; $p = 0.847$) and patients with nrAIDs (39/414; 9.4%; $p = 0.552$), but higher than that reported by patients with other rAIDs (235/3098; 7.6%; $p = 0.005$; Fig. 1).

Characteristics of SLE patients reporting a BI

Among respondents with SLE who reported a BI, a vast majority was of female sex ($N = 84$; 93.3%), which was comparable to SLE patients not reporting a BI ($N = 714$; 94.8%). The mean (S.D.) age of SLE patients who reported a BI was 38.8 (11.1) compared to 41.5 (13.3) for patients not reporting a BI. Caucasians constituted the most represented ethnic group in SLE patients reporting a BI ($N = 32$; 36.8%), as well as in patients not reporting a BI ($N = 238$; 33.2%), followed by Asians ($N = 29$; 33.7% among SLE patients reporting a BI, and $N = 226$; 31.5% among SLE patients not reporting a BI).

In univariable logistic regression analyses, we found no statistically significant association with the occurrence of BI among the analysed factors in our SLE population. Notably, GC use did not favour the occurrence of BI (OR: 0.90; 95% CI: 0.58–1.40; $p = 0.632$), nor did

treatment with hydroxychloroquine (HCQ; OR: 0.85; 95% CI: 0.53–1.35; $p = 0.487$) or conventional immunosuppressive drugs, including azathioprine (AZA; OR: 1.11; 95% CI: 0.66–1.88; $p = 0.697$), methotrexate (MTX; OR: 0.81; 95% CI: 0.40–1.61; $p = 0.542$), or mycophenolic acid (MPA; OR: 1.10; 95% CI: 0.64–1.88; $p = 0.722$). Characteristics of SLE patients reporting a BI, compared with SLE patients not reporting a BI, are detailed in Fig. 2.

Comparisons of BI characteristics between patients with SLE and HCs

The median (IQR) duration of BI was 10 [6–16] days in patients with SLE, and 8 [6–15] days in HCs, yielding no statistically significant difference in unadjusted ($\beta = 0.98$; 95% CI: -6.10–8.07; $p = 0.786$) and adjusted linear regression models ($\beta = 0.12$; 95% CI: -8.33–8.56; $p = 0.978$). In multivariable logistic regression adjusted for age, sex, and ethnicity, patients with SLE reported a higher occurrence of chest pain (OR: 2.33; 95% CI: 1.16–4.68; $p = 0.017$) and joint pain (OR: 3.38; 95% CI: 1.89–6.04; $p < 0.001$), but a lower occurrence of loss of taste (OR: 0.54; 95% CI: 0.30–0.99; $p = 0.045$) compared with HC. No other statistically significant differences in reported symptoms were found between the two groups. The proportion of SLE patients who reported a BI did not differ from the proportion of HCs who reported a BI with regard to hospitalisation (OR: 2.98; 95% CI: 0.82–10.82; $p = 0.098$) or the need for advanced treatment for COVID-19 (OR: 1.89; 95% CI: 0.62–5.77; $p = 0.262$). Characteristics of BIs in patients with SLE compared with HCs are detailed in Fig. 3.

Comparisons of BI characteristics between patients with SLE and patients with other rAIDs

The median (IQR) time to symptom resolution of BI was 14 [7–29] days in patients with rAIDs, which was longer compared to patients with SLE in unadjusted ($\beta = -14.00$; 95% CI: -25.42–2.59; $p = 0.017$) and adjusted ($\beta = -12.47$; 95% CI: -24.80–0.14; $p = 0.048$) linear regression models. The overall occurrence of any symptoms was comparable between the two groups (OR: 1.49; 95% CI: 0.58–3.78; $p = 0.405$). Compared with patients with other rAIDs, patients with SLE more frequently experienced chest pain (OR: 1.98; 95% CI: 1.01–3.88; $p = 0.046$) and running nose (OR: 1.86; 95% CI: 1.08–3.20; $p = 0.025$), and less frequently experienced loss of smell (OR: 0.54; 95% CI: 0.30–0.98; $p = 0.042$) and loss of taste (OR: 0.40; 95% CI: 0.22–0.74; $p = 0.003$). No significant difference was found in hospitalisation frequencies (OR: 1.39; 95% CI: 0.47–4.12; $p = 0.553$) or the need for advanced treatment for COVID-19 (OR: 0.71; 95% CI: 0.25–1.77; $p = 0.465$) between the two groups. Results from multivariable logistic regression

Table 1 Demographics and clinical data of the study population

	SLE (N = 852)	HC (N = 2671)	rAID (N = 3098)	nrAID (N = 414)
Patient characteristics				
Age; mean (S.D.)	41.2 (13.1); N = 839	39.9 (13.2); N = 2616	51.7 (14.1); N = 3051	44.7 (14.1); N = 402
Female gender; n (%)	798 (94.7); N = 843	1574 (59.8); N = 2631	2470 (80.7); N = 3062	339 (82.9); N = 409
Ethnicity; n (%)	N = 804	N = 2537	N = 2998	N = 397
African	80 (10.0)	88 (3.5)	127 (4.2)	3 (0.8)
Asian	255 (31.7)	693 (27.3)	591 (19.7)	56 (14.1)
Caucasian	270 (33.6)	739 (29.1)	1762 (58.8)	220 (55.4)
Hispanic	108 (13.4)	714 (28.1)	280 (9.3)	81 (20.4)
Others	91 (11.3)	303 (11.9)	238 (7.9)	37 (9.3)
Self-reported disease activity status; n (%)	N = 611	N = 34	N = 2500	N = 286
Inactive or in remission	187 (30.6)	4 (11.8)	473 (18.9)	84 (29.4)
Active but stable and manageable	258 (42.2)	19 (55.9)	1170 (46.8)	132 (46.2)
Active and improving	39 (6.4)	2 (5.9)	187 (7.5)	20 (7.0)
Active and worsening	70 (11.5)	5 (14.7)	422 (16.9)	17 (5.9)
Uncertain	57 (9.3)	4 (11.8)	248 (9.9)	33 (11.5)
Medications				
Biologics; n (%)				
Anti-TNF agents	4 (0.5)	2 (0.1)	318 (10.3)	9 (2.2)
Rituximab	25 (2.9)	0 (0.0)	207 (6.7)	2 (0.5)
Glucocorticoids; n (%)				
Glucocorticoid use	516 (60.6)	4 (0.1)	946 (30.5)	41 (9.9)
Prednisone eq. dose \geq 10 mg/day	132 (15.5)	2 (0.1)	267 (8.6)	14 (3.4)
Hydroxychloroquine; n (%)	598 (70.2)	0 (0.0)	596 (19.2)	12 (2.9)
Immunosuppressants; n (%)				
Azathioprine	174 (20.4)	0 (0.0)	150 (4.8)	18 (4.3)
Calcineurin inhibitors	41 (4.8)	1 (0.0)	65 (2.1)	7 (1.7)
Cyclophosphamide	18 (2.1)	0 (0.0)	33 (1.1)	1 (0.2)
Leflunomide	20 (2.3)	0 (0.0)	173 (5.6)	0 (0.0)
Methotrexate	111 (13.0)	5 (0.2)	1077 (34.8)	13 (3.1)
Mycophenolic acid	166 (19.5)	1 (0.0)	256 (8.3)	4 (1.0)
Sulfasalazine	15 (1.8)	2 (0.1)	261 (8.4)	5 (1.2)
Intravenous immunoglobulin; n (%)	14 (1.6)	0 (0.0)	109 (3.5)	2 (0.5)
Small molecules; n (%)				
JAK inhibitors	2 (0.2)	0 (0.0)	81 (2.6)	1 (0.2)

Data are presented as numbers (percentage) or means (standard deviation). In case of missing values, numbers of patients with available data are indicated

eq. equivalent; HC healthy controls; JAK janus kinase; nrAID non-rheumatic autoimmune disease; rAID rheumatic autoimmune disease; S.D. standard deviation; SLE systemic lupus erythematosus; TNF tumour necrosis factor

of factors associated with BI between patients with SLE and patients with other rAIDs are illustrated in Fig. 4.

Comparisons of BI characteristics between patients with SLE and patients with nrAIDs

The median (IQR) BI duration was 10 (4–22.5) days in patients with nrAID and did not differ from that in patients with SLE in unadjusted ($\beta = -0.81$; 95% CI: -8.53 – 6.92 ; $p = 0.838$) and adjusted ($\beta = -0.25$; 95% CI: -8.78 – 8.28 ;

$p = 0.954$) linear regression models. In multivariable logistic regression analysis, the overall frequency of any reported symptoms was similar between the two groups (OR: 1.08; 95% CI: 0.22–5.30; $p = 0.922$). Patients with SLE reported higher occurrence of joint pain (OR: 2.44; 95% CI: 1.04–2.75; $p = 0.041$), but lower occurrence of loss of smell (OR: 0.32; 95% CI: 0.13–0.76; $p = 0.010$). No other BI characteristics were found to differ between the two groups. Results are shown in Fig. 5.




Fig. 1 COVID-19 BIs in the study population. Bar plots depicting the proportion of patients with SLE, HC, patients with rAID, and patients with nrAID who reported a BI. *BI* breakthrough infection; *HC* healthy controls; *nrAID* non-rheumatic autoimmune disease; *rAID* rheumatic autoimmune disease; *SLE* systemic lupus erythematosus

Discussion

Despite the multitude of studies on COVID-19 infection and COVID-19 vaccines since the start of the pandemic, there still exists a dearth of generalisable data on BIs in

patients with SLE. In the present study, we investigated COVID-19 BIs in patients with SLE compared with patients with rAIDs other than SLE, patients with nrAIDs, and HCs using data from the COVAD study. Our findings indicate that fully vaccinated SLE patients experience BIs with similar frequency compared to fully vaccinated HCs. In addition, the severity of reported BIs was comparable between SLE patients and HCs, and between SLE patients and disease controls, as were hospitalisation frequencies and the need for advanced treatment for COVID-19 infection.

We found the self-reported frequency of BIs to be 10.7% in SLE patients and 10.4% in HCs, which is higher than the reported rates in other cohorts of patients with rAIDs and nrAIDs, using the same definition of BI [23–25]. One survey from Southern India reported a prevalence of BIs of 1.1% among patients with rAIDs [23], and data from the EULAR COVAX registry demonstrated a frequency of BI of 0.7% in patients with rAIDs, and 1.1% in patients with nrAID [24]. Another study from the US found that in patients with rAIDs who developed a COVID-19 infection, only 4.7% of the infections were BIs [25]. These differences might be due to our study design, which was susceptible to selection and recall bias, meaning that patients who were more willing to respond to the e-survey were probably more likely to have had a COVID-19 infection.




Fig. 2 Factors associated with COVID-19 BIs in the SLE population. Forest plot illustrating results for SLE patients reporting a BI and SLE patients not reporting a BI, analysed by univariable logis-

tic regression. *BI* breakthrough infection; *CI* confidence interval; *OR* odds ratio; *SLE* systemic lupus erythematosus




Fig. 3 Characteristics of COVID-19 BIs in patients with SLE versus healthy controls. Forest plot illustrating results for SLE patients reporting a BI and HC reporting a BI, analysed by multivariable

logistic regression adjusting for age, sex, and ethnicity. *BI* breakthrough infection; *CI* confidence interval; *HC* healthy controls; *OR* odds ratio; *SLE* systemic lupus erythematosus





Fig. 4 Characteristics of COVID-19 BIs in patients with SLE versus patients with rAID. Forest plot illustrating results for SLE patients reporting a BI and rAID patients reporting a BI, analysed by multi-

variable logistic regression adjusting for age, sex, and ethnicity. *BI* breakthrough infection; *CI* confidence interval; *OR* odds ratio; *rAID* rheumatic autoimmune disease; *SLE* systemic lupus erythematosus

In this study, we found that the reported frequency and severity of BIs was comparable in patients with SLE and HCs. Therefore, SLE per se does not seem to predispose to BI in fully vaccinated subjects, nor is it a risk factor for

the degree of severity of a BI or poorer outcome post infections. Patients with rAIDs constitute a vulnerable population with a higher incidence of infections, including COVID-19 infection, and previous studies suggested that SLE patients

Fig. 5 Characteristics of COVID-19 BIs in patients with SLE versus patients with nrAID. Forest plot illustrating results for SLE patients reporting a BI and nrAID patients reporting a BI, analysed by multivariable logistic regression adjusting for age, sex, and ethnicity. *BI* breakthrough infection; *CI* confidence interval; *nrAID* non-rheumatic autoimmune disease; *OR* odds ratio; *SLE* systemic lupus erythematosus



were at an increased risk of hospitalisation due to COVID-19 infection [26–28]. However, whether SLE patients are at an increased risk of severe COVID-19 BIs remains controversial. Although some reports have highlighted an elevated risk of hospitalisation in this patient population when experiencing a COVID-19 BI [29], other studies have reported no difference in incidence or severe complications of COVID-19 BI between vaccinated SLE patients and the vaccinated general population [30]. Notably, in a previous study from the UK exploring the risk of COVID-19 among unvaccinated and vaccinated patients with SLE, defined as having at least one dose of a COVID-19 vaccine, the authors found a higher risk of COVID-19 infection and severe sequelae in unvaccinated SLE patients compared with unvaccinated HCs, but no differences among the vaccinated population [30]. Our finding of non-significant difference in BIs prevalence between patients with SLE and HCs is in the same direction, offering evidence that COVID-19 vaccination confers adequate protection to this high-risk population.

We observed no major differences between patients with SLE and patients with other rAIDs with regard to COVID-19 BI symptoms. However, patients with rAIDs were less likely to develop a BI compared with patients with SLE, which may be indicative of the vulnerability of the SLE population to viral infections. This might also be due to immunosuppressive drugs commonly used in SLE, e.g., mycophenolate mofetil which has been shown to impede immune responses to vaccination [31]. In addition, our finding may be explained by heightened awareness and increased perception of COVID-19 infection consequences in this control group, which included individuals with high coexistent cardiopulmonary disease burden, such as patients with SSC

or anti-synthetase syndrome [32–34]. This may have led to protective behaviours taken by this population, like physical distancing and shielding [35].

In our cohort of SLE patients, we did not identify any predictors of BI among the analysed clinical and demographic factors. We observed that the use of immunomodulating drugs, including HCQ, MPA, AZA, and MTX, was not associated with an increased odds of experiencing a BI. The use of immunosuppressants is a known risk factor for developing a COVID-19 BI [36, 37]. However, a study from the Netherlands reported that immunosuppressive therapy among patients with immune-mediated inflammatory disease was not associated with a higher incidence of BI in non-immunocompromised patients and HCs [38]. Previous studies have showed that the use of immunosuppressive agents, such as high daily doses of prednisone and belimumab, may be associated with a weak antibody response to COVID-19 vaccines [39, 40]. In the present study, we could not explore the relationship between biologics, including B cell targeting therapies, and the incidence of BIs due to the low number of SLE patients treated with these drugs among the respondents. Thus, further investigation is warranted for the exploration of these associations.

In our study, the overall frequency of any symptoms was similar among patients with SLE compared with disease groups. The increased occurrence of joint pain during BI in patients with SLE compared to HCs and with patients with nrAIDs, but not in patients with other rAIDs, may be due to underlying osteoarticular involvement, which is frequent in patients with rAIDs. COVID-19 has been associated with rheumatic musculoskeletal manifestations [41], and there is evidence that COVID-19 and rAIDs share some

pro-inflammatory pathways [42]. Thus, our findings suggest that COVID-19 may act as a trigger for exacerbating symptoms in patients with chronically inflamed joints in the context of an underlying pre-existing rheumatic disease, including SLE.

One important limitation of this study was that it relied on an online survey, which introduces selection bias. Hence, individuals without internet access and those from lower socioeconomic regions are likely to be less represented in the sampling [43]. Secondly, being based on a self-reported questionnaire, our study lacked data on mortality. Moreover, clinical manifestations as per standard practice in SLE studies, e.g., using tools such as Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI) [44] or British Isles Lupus Assessment Group (BILAG) [45], were not captured. Lastly, the self-reporting nature of the questionnaire introduces recall bias. Nonetheless, a major strength was that COVAD is one of the largest studies of COVID-19, encompassing a global sample that is diverse with respect to demographics and comorbidities. Furthermore, the questionnaire included an extensive list of factors, including patient individual demographics, number of vaccine doses, therapy received, and details on BI clinical presentation, which facilitated in-depth analysis of multiple factors in relation to COVID-19 BIs.

In summary, we herein report a comparable prevalence of COVID-19 BIs across fully vaccinated SLE patients, HCs, and patients with nrAIDs, though a higher prevalence compared to that of patients with rAIDs. Our results suggest that COVID-19 vaccination confers similar protection against COVID-19 infection, in terms of frequency and severity, in patients with SLE compared with the healthy population. Finally, along with previous studies which have been reassuring concerning vaccine safety [18], our findings lend support for encouraging full vaccination in patients with SLE.

Conflict of interest

E.N. has received speaker honoraria/participated in advisory boards for Celltrion, Pfizer, Sanofi, Gilead, Galapagos, AbbVie, and Lilly, and holds research grants from Pfizer and Lilly. J.B.L. has received speaker honoraria/participated in advisory boards for Sanofi Genzyme, Roche, and Biogen. None is related to this manuscript. H.C. was supported by the National Institution for Health Research Manchester Biomedical Research Centre Funding Scheme. The views expressed in this publication are those of the authors and not necessarily those of the NHS, National Institute for Health Research, or Department of Health. H.C. has received grant support from Eli Lilly and UCB, consulting fees from Novartis, Eli Lilly, Orphazyme, Astra Zeneca, speaker for UCB, and Biogen. I.P. has received research funding and/or

honoraria from Amgen, AstraZeneca, Aurinia Pharmaceuticals, Eli Lilly and Company, Gilead Sciences, GlaxoSmith-Kline, Janssen Pharmaceuticals, Novartis and F. Hoffmann-La Roche AG. The other authors have no conflict of interest relevant to this manuscript.

Supplementary Information The online version contains supplementary material available at <https://doi.org/10.1007/s00296-024-05682-6>.

Acknowledgements COVID-19 Vaccination in Autoimmune Diseases (COVAD) Study Group: COVAD Study Group: The complete list of members of the COVAD Study Group as well as their affiliations are provided in the Supplementary Material.

Bhupen Barman, Yogesh Preet Singh, Rajiv Ranjan, Avinash Jain, Sapan C Pandya, Rakesh Kumar Pilania, Aman Sharma, Manesh Manoj M, Vikas Gupta, Chengappa G Kavadiachanda, Pradeepta Sekhar Patro, Sajal Ajmani, Sanat Phatak, Rudra Prosad Goswami, Abhra Chandra Chowdhury, Ashish Jacob Mathew, Padnamabha Shenoy, Ajay Asranna, Keerthi Talari Bommakanti, Anuj Shukla, Arun Kumar R Pandey, Kunal Chandwar, Sinan Kardes, Döndü Üsküdar Cansu, Minchul Kim, Ashima Makol, Tulika Chatterjee, John D Pauling, Chris Wincup, Lorenzo Cavagna, Nicoletta Del Papa, Gianluca Sambataro, Atzeni Fabiola, Marcello Govoni, Simone Parisi, Elena Bartoloni Bocci, Gian Domenico Sebastiani, Enrico Fusaro, Marco Sebastiani, Luca Quartuccio, Franco Franceschini, Pier Paolo Sainaghi, Giovanni Orsolini, Rossella De Angelis, Maria Giovanna Danielli, Vincenzo Venerito, Marcin Milchert, Lisa S Traboco, Suryo Anggoro Kusumo Wibowo, Erick Adrian Zamora Tehozol, Jorge Rojas Serrano, Ignacio García-De La Torre, Jesús Loarce-Martos, Sergio Prieto-González, Albert Gil-Vila, Raquel Aranega Gonzalez, Masataka Kuwana, Akira Yoshida, Ran Nakashima, Shinji Sato, Naoki Kimura, Yuko Kaneko, Johannes Knitz, Stylianos Tomaras, Margarita Aleksandrovna Gromova, Or Aharonov, Tamer A Gheita, Ihsane Hmamouchi, Leonardo Santos Hoff, Margherita Giannini, Francois Maurier, Julien Campagne, Alain Meyer, Melinda Nagy-Vincze, Daman Langguth, Vidya Limaye, Merrilee Needham, Nilesh Srivastav, Marie Hudson, Océane Landon-Cardinal, Syahrul Sazliana Shaharir, Wilmer Gerardo Rojas Zuleta, José António Pereira Silva, João Eurico Fonseca, Olena Zimba. The authors are grateful to all respondents for filling out the questionnaire. The authors also thank The Myositis Association, Myositis India, Myositis UK, Myositis Support and Understanding, the Myositis Global Network, Deutsche Gesellschaft für Muskelkranke e. V. (DGM), Dutch and Swedish Myositis patient support groups, Cure JM, Cure IBM, Sjögren's India Foundation, Patients Engage, Scleroderma India, Lupus UK, Lupus Sweden (Riksföreningen för SLE), Emirates Arthritis Foundation, EULAR PARE, ArLAR research group, AAAA patient group, APLAR myositis special interest group, Thai Rheumatism association, PANLAR, NRAS, Anti-Synthetase Syndrome support group, and various other patient support groups and organizations for their contribution in the dissemination of this survey. Finally, the authors wish to thank all members of the COVAD study group for their invaluable role in data collection.

Author contributions Conceptualisation: E.N., L.G., I.P. Data acquisition: All authors. Data curation: E.K.O., J.L., E.N., L.G., I.P. Formal analysis: J.L., L.G., I.P. Funding acquisition: L.G., I.P. Investigation: J.L., E.N., L.G., I.P. Methodology: J.L., E.N., L.G., I.P. Software: L.G., I.P. Visualization: J.L., L.G., I.P. Writing—original draft: L.P., J.L., E.K.O. I.P. Writing—review and editing: All authors. Disclaimer: No part of this manuscript is copied or published elsewhere in whole or in part. All co-authors take full responsibility for the integrity and accuracy of all aspects of the work.

Funding Open access funding provided by Karolinska Institute. The authors were supported by grants from the Swedish Rheumatism

Association (R-969696), King Gustaf V's 80-year Foundation (FAI-2020–0741), Swedish Society of Medicine (SLS-974449), Nyckelfonden (OLL-974804), Professor Nanna Svartz Foundation (2021–00436), Ulla and Roland Gustafsson Foundation (2021–26), Region Stockholm (FoUI-955483), and Karolinska Institutet.

Data availability The datasets generated and/or analyzed during the current study are not publicly available but are available from the corresponding author upon reasonable request.

Declarations

Ethical approval and informed consent An initial segment in the online survey served to obtain informed consent from the study participants. The results are reported in compliance with the Checklist for Reporting Results of the Internet E-surveys (CHERRIES). The ethics committee of Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS) granted approval for the study (IEC code: 2021–143-IP-EXP-39).

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.






















References

- Haas EJ, Angulo FJ, McLaughlin JM, Anis E, Singer SR, Khan F et al (2021) Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. *Lancet* 397(10287):1819–1829
- Lopez Bernal J, Andrews N, Gower C, Robertson C, Stowe J, Tessier E et al (2021) Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study. *BMJ* 373:n1088
- Watson OJ, Barnsley G, Toor J, Hogan AB, Winskill P, Ghani AC (2022) Global impact of the first year of COVID-19 vaccination: a mathematical modelling study. *Lancet Infect Dis* 22(9):1293–1302
- Liu Q, Qin C, Liu M, Liu J (2021) Effectiveness and safety of SARS-CoV-2 vaccine in real-world studies: a systematic review and meta-analysis. *Infect Dis Poverty* 10(1):132
- Suthar AB, Wang J, Seffren V, Wiegand RE, Griffing S, Zell E (2022) Public health impact of covid-19 vaccines in the US: observational study. *BMJ* 377:e069317
- Lee CJ, Woo W, Kim AY, Yon DK, Lee SW, Koyanagi A et al (2022) Clinical manifestations of COVID-19 breakthrough infections: a systematic review and meta-analysis. *J Med Virol* 94(9):4234–4245
- Xu C, Yi Z, Cai R, Chen R, Thong BY, Mu R (2021) Clinical outcomes of COVID-19 in patients with rheumatic diseases: a systematic review and meta-analysis of global data. *Autoimmun Rev* 20(4):102778
- Mehta P, Gasparyan AY, Zimba O, Kitas GD (2022) Systemic lupus erythematosus in the light of the COVID-19 pandemic: infection, vaccination, and impact on disease management. *Clin Rheumatol* 41(9):2893–2910
- Ugarte-Gil MF, Alarcón GS, Izadi Z, Duarte-García A, Reátegui-Sokolova C, Clarke AE et al (2022) Characteristics associated with poor COVID-19 outcomes in individuals with systemic lupus erythematosus: data from the COVID-19 Global Rheumatology Alliance. *Ann Rheum Dis* 81(7):970–978
- Gendebien Z, von Frenckell C, Ribbens C, André B, Thys M, Gangolf M et al (2021) Systematic analysis of COVID-19 infection and symptoms in a systemic lupus erythematosus population: correlation with disease characteristics, hydroxychloroquine use and immunosuppressive treatments. *Ann Rheum Dis* 80:e94
- Ramirez GA, Argolini LM, Bellocchi C, Moroni L, Della-Torre E, Farina N et al (2021) Impact of the COVID-19 pandemic in patients with systemic lupus erythematosus throughout one year. *Clin Immunol* 231:108845
- Marques CDL, Kakehasi AM, Pinheiro MM, Mota LMH, Albuquerque CP, Silva CR et al (2021) High levels of immunosuppression are related to unfavourable outcomes in hospitalised patients with rheumatic diseases and COVID-19: first results of Reuma-CoV Brasil registry. *RMD Open* 7(1):e001461corr1
- Sarin KY, Zheng H, Chaichian Y, Arunachalam PS, Swaminathan G, Eschholz A et al (2024) Impaired innate and adaptive immune responses to BNT162b2 SARS-CoV-2 vaccination in systemic lupus erythematosus. *JCI Insight*. <https://doi.org/10.1172/jci.insight.176556>
- Ferri C, Ursini F, Gragnani L, Raimondo V, Giuggioli D, Foti R et al (2021) Impaired immunogenicity to COVID-19 vaccines in autoimmune systemic diseases: High prevalence of non-response in different patients' subgroups. *J Autoimmun* 125:102744
- Curtis JR, Johnson SR, Anthony DD, Arasaratnam RJ, Baden LR, Bass AR et al (2023) American college of rheumatology guidance for COVID-19 vaccination in patients with rheumatic and musculoskeletal diseases: version 5. *Arthritis Rheumatol* 75(1):E1–E16
- Landewé RBM, Kroon FPB, Alunno A, Najm A, Bijlsma JW, Burmester GR et al (2022) EULAR recommendations for the management and vaccination of people with rheumatic and musculoskeletal diseases in the context of SARS-CoV-2: the November 2021 update. *Ann Rheum Dis* 81(12):1628–1639
- Ko T, Dendle C, Woolley I, Morand E, Antony A (2021) SARS-CoV-2 vaccine acceptance in patients with rheumatic diseases: a cross-sectional study. *Hum Vaccin Immunother* 17(11):4048–4056
- Naveen R, Nikiphorou E, Joshi M, Sen P, Lindblom J, Agarwal V et al (2023) Safety and tolerance of vaccines against SARS-CoV-2 infection in systemic lupus erythematosus: results from the COVAD study. *Rheumatology (Oxford)* 62(7):2453–2463
- Sen P, Gupta L, Lilleker JB, Aggarwal V, Kardes S, Milchert M et al (2022) COVID-19 vaccination in autoimmune disease (COVAD) survey protocol. *Rheumatol Int* 42(1):23–29
- Fazal ZZ, Sen P, Joshi M, Ravichandran N, Lilleker JB, Agarwal V et al (2022) COVAD survey 2 long-term outcomes: unmet need and protocol. *Rheumatol Int* 42(12):2151–2158
- Gaur PS, Zimba O, Agarwal V, Gupta L (2020) Reporting survey based studies - a primer for authors. *J Korean Med Sci* 35(45):e398
- Eysenbach G (2004) Improving the quality of Web surveys: the Checklist for Reporting Results of Internet E-Surveys (CHERRIES). *J Med Internet Res*. Canada 6:e34
- Mohanasundaram K, Santhanam S, Natarajan R, Murugesan H, Nambi T, Chilikuri B et al (2022) Covid-19 vaccination in autoimmune rheumatic diseases: a multi-center survey from southern India. *Int J Rheum Dis* 25(9):1046–1052
- Machado PM, Lawson-Tovey S, Strangfeld A, Mateus EF, Hyrich KL, Gossec L et al (2022) Safety of vaccination against

- SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry. *Ann Rheum Dis* 81(5):695–709
25. Cook C, Patel NJ, D'Silva KM, Hsu TY, DiIorio M, Prisco L et al (2022) Clinical characteristics and outcomes of COVID-19 breakthrough infections among vaccinated patients with systemic autoimmune rheumatic diseases. *Ann Rheum Dis*. England 81:289–91
 26. Cordtz R, Kristensen S, Dalgaard LPH, Westermann R, Duch K, Lindhardsen J et al (2021) Incidence of COVID-19 hospitalisation in patients with systemic lupus erythematosus: a Nationwide Cohort Study from Denmark. *J Clin Med* 10(17):3842
 27. Bertoglio IM, Valim JML, Daffre D, Aikawa NE, Silva CA, Bonfá E et al (2021) Poor prognosis of COVID-19 acute respiratory distress syndrome in lupus erythematosus: nationwide cross-sectional population study of 252 119 patients. *ACR Open Rheumatol* 3(11):804–811
 28. Raiker R, Pakhchanian H, DeYoung C, Gupta L, Kardeş S, Ahmed S et al (2021) Short term outcomes of COVID-19 in lupus: propensity score matched analysis from a nationwide multi-centric research network. *J Autoimmun* 125:102730
 29. Liew J, Gianfrancesco M, Harrison C, Izadi Z, Rush S, Lawson-Tovey S et al (2022) SARS-CoV-2 breakthrough infections among vaccinated individuals with rheumatic disease: results from the COVID-19 Global Rheumatology Alliance provider registry. *RMD Open* 8(1):e002187
 30. Jiang X, Sparks J, Wallace Z, Deng X, Li H, Lu N et al (2023) Risk of COVID-19 among unvaccinated and vaccinated patients with systemic lupus erythematosus: a general population study. *RMD Open*. <https://doi.org/10.1136/rmdopen-2022-002839>
 31. van Sleen Y, van der Geest KSM, Huckriede ALW, van Baarle D, Brouwer E (2023) Effect of DMARDs on the immunogenicity of vaccines. *Nat Rev Rheumatol* 19(9):560–575
 32. Conrad N, Verbeke G, Molenberghs G, Goetschalckx L, Callender T, Cambridge G et al (2022) Autoimmune diseases and cardiovascular risk: a population-based study on 19 autoimmune diseases and 12 cardiovascular diseases in 22 million individuals in the UK. *Lancet* 400(10354):733–743
 33. Ahmed S, Gupta L, Kuwana M, Pauling JD, Day J, Ravichandran N et al (2024) Correlates of breakthrough COVID-19 in vaccinated patients with systemic sclerosis: survival analysis from a multicentre international patient-reported survey. *Rheumatol Int* 44(1):89–97
 34. Hoff LS, Ravichandran N, Shinjo SK, Day J, Sen P, Junior JG et al (2023) COVID-19 severity and vaccine breakthrough infections in idiopathic inflammatory myopathies, other systemic autoimmune and inflammatory diseases, and healthy controls: a multicenter cross-sectional study from the COVID-19 Vaccination in Autoimmune Diseases (COVAD) survey. *Rheumatol Int* 43(1):47–58
 35. Cook C, Cox H, Fu X, Zhang Y, Stone JH, Choi HK et al (2021) Perceived risk and associated shielding behaviors in patients with rheumatoid arthritis during the coronavirus 2019 pandemic. *ACR Open Rheumatol* 3(12):834–841
 36. Liu C, Lee J, Ta C, Soroush A, Rogers JR, Kim JH et al (2022) Risk factors associated with SARS-CoV-2 breakthrough infections in fully mRNA-vaccinated individuals: retrospective analysis. *JMIR Public Health Surveill* 8(5):e35311
 37. Patel NJ, Wang X, Fu X, Kawano Y, Cook C, Vanni KMM et al (2023) Factors associated with COVID-19 breakthrough infection among vaccinated patients with rheumatic diseases: a cohort study. *Semin Arthritis Rheum* 58:152108
 38. Boekel L, Stalman EW, Wiese L, Hooijberg F, van Dam KPJ, Besten YR et al (2022) Breakthrough SARS-CoV-2 infections with the delta (B.1.617.2) variant in vaccinated patients with immune-mediated inflammatory diseases using immunosuppressants: a substudy of two prospective cohort studies. *Lancet Rheumatol*. 4(6):e417–e29
 39. Parsons C, Rubio J, Boulougoura A, Krishfield S, Kyttaris V (2023) Predictors of a weak antibody response to COVID-19 mRNA vaccine in systemic lupus erythematosus. *Rheumatol Int* 43(9):1621–1627
 40. Larsen ES, Nilsson AC, Möller S, Voss AB, Johansen IS (2023) Immunogenicity and risk of disease flare after a three-dose regimen with SARS-CoV-2 vaccination in patients with systemic lupus erythematosus: results from the prospective cohort study COVAC-SLE. *Clin Exp Rheumatol* 41(3):676–684
 41. Ciaffi J, Vanni E, Mancarella L, Brusi V, Lisi L, Pignatti F et al (2023) Post-acute COVID-19 joint pain and new onset of rheumatic musculoskeletal diseases: a systematic review. *Diagnostics (Basel)* 13(11):1850
 42. Schett G, Manger B, Simon D, Caporali R (2020) COVID-19 revisiting inflammatory pathways of arthritis. *Nat Rev Rheumatol* 16(8):465–470
 43. Veinot TC, Mitchell H, Ancker JS (2018) Good intentions are not enough: how informatics interventions can worsen inequality. *J Am Med Inform Assoc* 25(8):1080–1088
 44. Uribe AG, Vilá LM, McGwin G Jr, Sanchez ML, Reveille JD, Alarcón GS (2004) The systemic lupus activity measure-revised, the mexican Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), and a modified SLEDAI-2K are adequate instruments to measure disease activity in systemic lupus erythematosus. *J Rheumatol* 31(10):1934–1940
 45. Gordon C, Sutcliffe N, Skan J, Stoll T, Isenberg DA (2003) Definition and treatment of lupus flares measured by the BILAG index. *Rheumatology (Oxford)* 42(11):1372–1379

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Authors and Affiliations

Leonardo Palazzo¹  · Julius Lindblom¹  · Emelie Kihlgren Olsson¹  · Elena Nikiphorou^{2,3}  · Chris Wincup^{4,5}  · Sreoshy Saha⁶  · Syahrul Sazliyana Shaharir⁷  · Wanruchada Katchamart⁸  · Phonpen Akarawatcharangura Goo⁹  · Lisa Traboco¹⁰  · Yi-Ming Chen^{11,12}  · James B. Lilleker^{13,14}  · Arvind Nune¹⁵  · John D. Pauling^{16,17}  · Vishwesh Agarwal¹⁸  · Dey Dzifa¹⁹ · Carlos Enrique Toro Gutiérrez²⁰  · Carlo V. Caballero-Urbe²¹  · Hector Chinoy^{13,22,23}  · COVAD Study Group · Vikas Agarwal²⁴  · Latika Gupta^{13,25}  · Ioannis Parodis^{1,26} 

✉ Ioannis Parodis
ioannis.parodis@ki.se

¹ Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden

- ² Centre for Rheumatic Diseases, King's College London, London, UK
- ³ Rheumatology Department, King's College Hospital, London, UK
- ⁴ Division of Medicine, Department of Rheumatology, Rayne Institute, University College London, London, UK
- ⁵ Centre for Adolescent Rheumatology Versus Arthritis at UCL, UCLH, GOSH, London, UK
- ⁶ Mymensingh Medical College, Mymensingh, Bangladesh
- ⁷ Faculty of Medicine, Universiti Kebangsaan Malaysia, Cheras, Kuala Lumpur, Malaysia
- ⁸ Division of Rheumatology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand
- ⁹ Department of Medicine, Queen Savang Vadhana Memorial Hospital, Chonburi, Thailand
- ¹⁰ Section of Rheumatology, Department of Medicine, St. Luke's Medical Center-Global City, Taguig, Philippines
- ¹¹ Division of Allergy, Immunology and Rheumatology, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung City, Taiwan, Republic of China
- ¹² Department of Medical Research, Taichung Veterans General Hospital, Taichung, Taiwan, Republic of China
- ¹³ Division of Musculoskeletal and Dermatological Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, Centre for Musculoskeletal Research, Manchester Academic Health Science Centre, The University of Manchester, Manchester, UK
- ¹⁴ Manchester Centre for Clinical Neurosciences, Salford Royal NHS Foundation Trust, Salford, UK
- ¹⁵ Southport and Ormskirk Hospital NHS Trust, Southport, UK
- ¹⁶ Bristol Medical School Translational Health Sciences, Health Sciences, Bristol, UK
- ¹⁷ Department of Rheumatology, North Bristol NHS Trust, Bristol, UK
- ¹⁸ Mahatma Gandhi Mission Medical College, Navi Mumbai, Maharashtra, India
- ¹⁹ Rheumatology Unit, Department of Medicine and Therapeutics, University of Ghana Medical School, College of Health Sciences, Korle-Bu, Accra, Ghana
- ²⁰ Reference Center for Osteoporosis, Rheumatology and Dermatology, Pontificia Universidad Javeriana Cali, Cali, Colombia
- ²¹ Department of Medicine, Hospital Universidad del Norte, Barranquilla, Atlantico, Colombia
- ²² National Institute for Health Research Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, The University of Manchester, Manchester, UK
- ²³ Department of Rheumatology, Salford Royal Hospital, Northern Care Alliance NHS Foundation Trust, Salford, UK
- ²⁴ Department of Clinical Immunology and Rheumatology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India
- ²⁵ Department of Rheumatology, Royal Wolverhampton Hospitals NHS Trust, Wolverhampton, UK
- ²⁶ Department of Rheumatology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden